Patiromer and Diet/hrQoL in Chronic Dialysis
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention
In brief
This is a phase III, prospective, randomized, double-blind, placebo-controlled, single-center, pilot trial, aimed at assessing whether treatment with the oral potassium binder patiromer as compared to placebo allows withdrawal or down-titration of potassium dietary restriction without increasing the risk of hyperkalemia in chronic dialysis patients.
Key facts
- Study ID
- NCT06858280
- Run by
- Mario Negri Institute for Pharmacological Research
- People needed
- 40
- Starts
- 2025-07-08
- Expected to finish
- 2026-07-01
- Last updated by the study team
- 2025-09-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Nephrology Unit, ASST Papa Giovanni XXIII — Bergamo, BG, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.